Vertex Pharmaceuticals Acquires Crinetics for $10 Billion
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in an all-cash deal valued at approximately $10 billion. The acquisition, expected to close by Q3 2026, marks Vertex's expansion into new therapeutic areas beyond cystic fibrosis.
